Second Sight Medical Products Inc (EYES): Edward David Randolph , VP of Manufacturing of Second Sight Medical Products Inc sold 5,104 shares on Jun 3, 2016. The Insider selling transaction was reported by the company on Jun 7, 2016 to the Securities and Exchange Commission. The shares were sold at $4.01 per share for a total value of $20,467.04 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 7, 2016, Edward David Randolph (VP of Manufacturing) sold 5,104 shares at $4.01 per share price.On Jun 6, 2016, Robert J. Greenberg (Chairman of Board) sold 8,571 shares at $4.10 per share price.Also, On Dec 7, 2015, Anne-marie Juliette Ripley (VP of Regulatory Affairs) sold 2,500 shares at $5.50 per share price.
Shares of Second Sight Medical Products Inc (EYES) ended Friday, Jun 3, 2016 session in red amid volatile trading. The shares closed down -0.14 points or -3.45% at $3.92 with 1,96,982 shares getting traded. Post opening the session at $4.01, the shares hit an intraday low of $3.85 and an intraday high of $4.0715 and the price vacillated in this range throughout the day. The company has a market cap of $141 M and the number of outstanding shares has been calculated to be 3,60,37,309 shares. The 52-week high of Second Sight Medical Products Inc is $17.5 and the 52-week low is $3.4.
Second Sight Medical Products Inc. is a medical device company that develops manufactures and markets implantable visual prosthetics to restore some functional vision to blind patients. The Company’s product the Argus II System treats outer retinal degenerations such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision that normally sighted people have. The Argus II Retinal Prosthesis System consists of an implant a small portable computer and a pair of glasses with a miniature video camera. The Argus II system received Conformite Europeenne (CE) Mark approval for marketing and sales in the European Union (EU) and approval by the United States Food and Drug Administration (FDA) for marketing and sales in the United State. The Company also markets the Argus II system in Canada Turkey and at one medical center in Saudi Arabia.